Novo-Nordisk A/S (NVO)

The company now

Novo Nordisk, the Danish maker of Ozempic and Wegovy, reported second-quarter 2026 adjusted sales of DKK 78.5 billion on 4 August, up 7 percent at constant exchange rates, which set currency swings aside 1. Adjusted sales leave out one-time reversals of rebate provisions tied to the US 340B Drug Pricing Program, which brought no cash 1. The company then raised its 2026 outlook for adjusted sales growth to between 0 and minus 6 percent, from minus 4 to minus 12 percent 12.

Growth came from more patients rather than higher prices: GLP-1 volumes rose in both operating units while realised prices fell 1. The Wegovy pill, a daily weight-loss tablet launched in the US on 5 January, passed 265,000 weekly prescriptions in the week ending 17 July 1. Chief executive Mike Doustdar called the Wegovy family "a key growth driver" for 2026 1.

On 21 September the company set out its ambitions to 2030 in London, including more than five multi-blockbuster launches and revenue growth in line with large drug peers 4. In early October it said the FDA had extended its review of denecimig, a haemophilia A medicine, while a factory is fixed 7. The open question is the nine-month report due on 4 November 2026 1.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.